1. Quick Summary
Some cancers survive by switching off the immune response that would otherwise attack them. Certain drugs release those brakes and let immune cells act.
The results can be dramatic and durable, yet they occur in a fraction of patients. Understanding that difference is the field’s main problem.
2. What It Means
Tumour cells are the body’s own cells, so the immune system is normally restrained from attacking them. Cancers exploit those restraint mechanisms.
Checkpoint-blocking drugs interfere with the signals tumours use to switch immune cells off, restoring activity rather than attacking the tumour directly.
Response depends on whether immune cells are present and able to recognise the tumour in the first place, which varies enormously between tumours.
3. Why It Happens
Tumours differ in how visible they are to the immune system. Cancers with many mutations produce more abnormal proteins, giving the immune system more to recognise.
Some tumours exclude immune cells physically, creating an environment that treatments cannot easily penetrate.
The surrounding tissue matters, since supportive cells and signals can suppress immune activity locally.
Gut and systemic factors appear to influence response, which is an active and sometimes overstated area of research.
Immune activation has a cost: releasing restraint can cause inflammation in healthy tissue, and side effects can be serious.
Combination strategies dominate current work, pairing immunotherapy with treatments that make tumours more visible or more accessible to immune cells.
4. Real Examples
Checkpoint inhibitors: drugs that block the signals tumours use to suppress immune attack.
Biomarker testing: measuring tumour characteristics to predict who is likely to respond.
Combination trials: adding therapies intended to make a cold tumour visible to the immune system.
Cell therapies: engineering a patient’s own immune cells to recognise their cancer.
Immune-related side effects: inflammatory reactions in healthy organs that require careful management.
5. How It Affects Us
Treatment planning: biomarker testing increasingly determines whether immunotherapy is offered.
Trial design: combination studies are complex, and response patterns differ from conventional drugs.
Cost and access: these therapies are expensive and not equally available.
Expectation setting: durable remission is possible, but response is not the majority outcome.
6. Key Takeaways
- Immunotherapy releases existing restraint rather than attacking the tumour directly.
- Tumour visibility to the immune system strongly affects response.
- Side effects arise from genuine immune activation in healthy tissue.
- Combination approaches aim to convert non-responders into responders.